jRCT2031230340已完成不适用
A randomized, controlled, blinded study of ARCT-2301 as booster in healthy adults in Japan (Phase III)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 850
- 主要终点
- Geometric mean titer (GMT)
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Individuals are participant (irrespective of gender) >=18 years of age at Informed consent.
- •Participant or legally authorized representatives must freely provide documented informed consent prior to study procedures being performed.
- •Individuals must have been previously vaccinated with mRNA COVID-19 vaccine and satisfy the following criteria.
- •Received 2~4 doses with authorized mRNA COVID-19 vaccine (monovalent COMIRNATY or monovalent SPIKEVAX)
- •Received the last booster dose of COMIRNATY RTU intramuscular injection ([bivalent: Wuhan strain/Omicron BA.1] or [bivalent: Wuhan strain/Omicron BA.4/5])
- •At least 3 months have passed since the last vaccination at the time of screening
- •Receipt of these vaccines is supported by any documents and application software
排除标准
- •Individuals with acute medical illness or febrile illness, including oral temperature >= 37.5 degree Celsius within 1 day prior to Screening. These individuals may be offered the opportunity to enter the study after fever and illness has stabilized. Participants with suspected or confirmed COVID-19 should be excluded and referred for medical care. Rescreening will be permitted for individuals who presented with suspected COVID-19 if another cause is confirmed.
- •Individuals with a positive SARS-CoV-2 rapid antigen test at Screening
- •Individuals with a history of COVID-19 with ongoing sequelae of COVID-19 infection within 6 months
结局指标
主要结局
Geometric mean titer (GMT)
时间窗: Day 29
Geometric mean titer of neutralizing antibodies against SARS-CoV-2 (Omicron strain BA.4-5)
Seroresponse rate (SRR)
时间窗: Day 29
Seroresponse rate of neutralizing antibodies against SARS-CoV-2 (Omicron strain BA.4-5)
次要结局
未报告次要终点
研究者
相似试验
招募中
不适用
TO-209 Phase III Clinical StudyjRCT2041250027Torii Pharmaceutical Co.,Ltd760
进行中（未招募）
不适用
X01-315-02 / ?A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7R Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma? - Allovectin-7R Immunotherapy for Metastatic Melanoma (A.I.M.M.)Recurrent metastatic melanomaMedDRA version: 9.1Level: LLTClassification code 10027481Term: Metastatic melanomaEUCTR2007-004120-21-ITVICAL INCORPORATED375
进行中（未招募）
3 期
AYD001 Phase III Clinical TrialPatients with chronic renal failure undergoing hemodialysisJPRN-jRCT2031210570Asaoka Kuniharu60
招募中
不适用
JCOG2315: A randomized controlled phase III study comparing local steroid injection alone versus combination therapy of local steroid injection and oral steroid administration for the prevention of esophageal stricture after wide-spreading endoscopic submucosal dissection (E-COMBI)jRCTs031240545420
未知
3 期
KD-357 Phase III Studypreexposure prophylaxis against rabiesJPRN-jRCT2080222145The Chemo-Sero-Therapeutic Research Institute200